If you live in Washington and are researching compounded GLP-1 medications, this page is meant to be the practical version of that research: how access actually works in the state, what Washington’s regulators have said about compounded semaglutide and tirzepatide, what treatment costs, and how the providers serving Washington compare on published cash prices. Pricing in this category is often hard to pin down, so we link every number to a public source and tell you plainly when a provider does not publish one. One disclosure up front: this site is operated by Gentle Health, a telehealth practice that offers compounded GLP-1 treatment in Washington. Gentle Health appears in the comparison table below on the same terms as every other provider listed.
How compounded GLP-1 access works in Washington
Washington does not require an in-person visit before a physician can evaluate you and, if appropriate, prescribe a non-controlled medication through telehealth. That makes the process straightforward for patients from Seattle to Spokane: you complete a medical intake online, meet with a licensed clinician by video or complete an asynchronous evaluation where permitted, and, if treatment is appropriate, a prescription is sent to a pharmacy that ships to your address. Distance is the point of the model rather than an obstacle to it. Current dose tiers and pricing for the state are on our Washington page, and readers in the Tri-Cities, central Washington or the Puget Sound corridor can start from Kennewick, Yakima or Seattle instead.
At Gentle Health, care is provided by James Simmons, MD, who is licensed in Washington through the Interstate Medical Licensure Compact (license IMLC.MD.70162198, state board record), the expedited licensing pathway that participating states, including Washington, use to license qualified physicians across state lines (IMLCC). Dr. Simmons reviews each patient’s history, medications, and labs where indicated, decides whether a GLP-1 is appropriate at all, and follows patients over time, adjusting dose or stopping treatment when that is the right call. There is no membership fee and no insurance billing; the monthly price includes the medical care and the medication.
The sequence for a Washington patient looks like this:
- Complete an online health intake with medical history and current medications.
- Have a telehealth evaluation with Dr. Simmons.
- If treatment is appropriate, a prescription goes to a licensed compounding pharmacy.
- Medication ships to your home in Washington, with follow-up visits and dose adjustments handled online.
Treatment is subject to medical evaluation. Not everyone is a candidate, and a legitimate telehealth practice should be willing to say no.
Washington rules worth knowing
Washington is generally considered a telehealth-friendly state, but it is also one of the states whose regulators have spoken directly about compounded GLP-1s. Three things are worth understanding.
Telehealth prescribing follows the in-person standard of care. The Washington State Department of Health treats telemedicine as a delivery method, not a lower standard: an appropriate evaluation, a documented provider-patient relationship, and medical necessity are required, just as they would be in an office (WA DOH telehealth resources; CCHP’s Washington summary). Non-controlled medications, which include GLP-1s, can be prescribed after a telehealth evaluation without a prior in-person visit. Washington does have a separate rule for audio-only telemedicine: for those phone-only visits to be reimbursed at parity, the patient generally needs an established relationship with the provider, a window the legislature extended from two years to three in 2024. Video-based care, the model most GLP-1 telehealth practices use, is not subject to that limitation.
The Pharmacy Quality Assurance Commission has a standing statement on compounded semaglutide. In August 2024, Washington’s Pharmacy Quality Assurance Commission issued a statement, published through the Washington Medical Commission, laying out the federal rules that govern semaglutide compounding (Statement of Compounding Semaglutide). The short version: no salt forms of semaglutide may be used in a compounded product; any semaglutide base must be pharmaceutical grade, accompanied by a valid certificate of analysis, and sourced from an establishment registered with the FDA and licensed in Washington; and pharmacies or pharmacists that compound or dispense non-compliant product face disciplinary action under state law (the statement cites RCW 18.64.026 and RCW 18.130.180, among others). The Washington State Board of Nursing re-circulated the statement in April 2025 and noted it remains current (Board of Nursing reminder).
The federal shortage era has ended, which narrows what can be compounded. For roughly two years, compounded GLP-1s were widely available because the FDA-approved versions were on the federal drug shortage list. In early 2025 the FDA declared the semaglutide and tirzepatide shortages resolved and clarified its enforcement policies for compounders as supply stabilized (FDA statement). Both shortages remain resolved as of July 2026, and in April 2026 the FDA went a step further, proposing to remove semaglutide and tirzepatide from the list of bulk substances that 503B outsourcing facilities may use in compounding, with a final determination still pending (Pharmacy Times coverage of the proposal). Off the shortage list, federal law prohibits compounding products that are “essentially copies” of commercially available drugs, with limited exceptions, such as a prescriber documenting a patient-specific clinical difference that the commercial product does not meet. Washington’s commission has said plainly that it expects licensees to follow those federal requirements. For patients, the practical takeaway is that compounded GLP-1s in Washington today should come from a pharmacy licensed in the state, prescribed for a documented individual reason, and any provider or pharmacy that cannot explain how it meets those conditions is worth avoiding.
Because the commission’s statement discusses specific FDA-approved products by name, a disclosure is required here: Gentle Health does not sell Ozempic, Wegovy, Mounjaro, or Zepbound. We offer compounded semaglutide and tirzepatide, which are different products. Gentle Health is not affiliated with, endorsed by, or connected to Novo Nordisk or Eli Lilly, the manufacturers of those brand medications.
Compounded semaglutide in Washington
Semaglutide is a GLP-1 receptor agonist, a class of medication that acts on appetite regulation and gastric emptying and is FDA-approved, in its brand forms, for type 2 diabetes and chronic weight management. Compounded semaglutide is a version of the molecule prepared by a licensed compounding pharmacy under a prescription written for a specific patient. It is not an FDA-approved product, it is not reviewed by the FDA for safety or effectiveness before dispensing, and clinical trial results from the approved brand products should not be assumed to apply to it. What compounding offers instead is formulation flexibility, such as oral forms and adjusted dosing, and, typically, a lower cash price.
In Washington, that flexibility comes with the guardrails described above: the pharmacy must be licensed in the state, the active ingredient must be pharmaceutical-grade semaglutide base with a certificate of analysis, and salt forms are not permitted.
Gentle Health offers compounded semaglutide to Washington patients in two forms:
- Oral compounded semaglutide: starting at $112 per month. A dissolvable form for patients who prefer to avoid injections.
- Injectable compounded semaglutide: starting at $135 per month. A once-weekly subcutaneous injection, supplied with dosing instructions and supplies.
Both prices are dose-tiered cash prices that include the telehealth evaluation and ongoing care with Dr. Simmons. There is no membership fee, no insurance is accepted or required, and treatment continues only as long as it makes clinical sense for you.
Compounded tirzepatide in Washington
Tirzepatide works on two receptor pathways, GLP-1 and GIP, and its brand forms are FDA-approved for type 2 diabetes and chronic weight management. As with semaglutide, compounded tirzepatide is a pharmacy-prepared product tied to an individual prescription: not FDA-approved, not pre-market reviewed, and governed in Washington by the same Pharmacy Quality Assurance Commission expectations around ingredient sourcing and federal compounding law. The FDA’s shortage-era enforcement flexibility for tirzepatide ended even earlier than semaglutide’s, in the first half of 2025, so the documented, patient-specific basis for a compounded prescription matters here too.
Some patients come to tirzepatide after semaglutide has not been a good fit, for reasons of tolerability or clinical response; that is a decision to make with a physician, not a marketing page.
Gentle Health offers injectable compounded tirzepatide starting at $169 per month for Washington patients. As with semaglutide, that is a dose-tiered cash price covering the medical evaluation, the medication, and follow-up care with Dr. Simmons. If tirzepatide is not appropriate for you, Dr. Simmons will say so.
Provider options in Washington: comparison table
Methodology: providers listed serve Washington via telehealth and offer compounded GLP-1s; prices come only from each provider’s own public pages as checked on the dates shown in each row (July 27-30, 2026), and where a provider does not publish a price we say “See site” rather than guess. Rows are alphabetical. Gentle Health operates this site.
| Provider | Care model | Compounded semaglutide (cash/mo) | Compounded tirzepatide (cash/mo) | Serves Washington | Insurance | Source |
|---|---|---|---|---|---|---|
| Gentle Health (this site) | Telehealth; care by James Simmons, MD; medication and visits in one published dose-tier schedule | From $112 oral / from $135 injectable | From $169 | Yes | Not accepted; cash-pay | gentle.health (verified 2026-07-30) |
| Henry Meds | Telehealth subscription; provider visits, medication, and supplies bundled | $247 after intro month (weekly injectable) | $349 after intro month (daily oral tablet) | See site | Not required; cash-pay | henrymeds.com (verified 2026-07-30) |
| Ivim Health | Telehealth; membership with app-based coaching; compounded and brand options | See site | See site | Yes (49 states + DC per Ivim) | Varies; compounded is cash-pay per Ivim | ivimhealth.com (verified 2026-07-27) |
| Mochi Health | Telehealth; $79/mo membership (promotional first month advertised), medication billed separately | See site | See site | Yes | Membership is cash; see site for visit coverage | joinmochi.com (verified 2026-07-30) |
| Sound Weight Loss | Washington-based telehealth clinic (nurse practitioner led) | See site | See site | Yes (Washington-focused) | See site | soundtelehealth.com (checked 2026-07-30; pricing not confirmed) |
Two notes on reading this table. First, structures differ: some providers bundle everything into one monthly price, while others charge a membership plus medication, so the comparable number is your total monthly cost, not the headline. Second, published prices in this category change often; treat every figure, including ours, as “as of the date checked” and confirm on the provider’s site before signing up.
Frequently asked questions
Is compounded semaglutide legal in Washington?
Compounding is a legal, regulated part of pharmacy practice in Washington, but it is bounded by federal law. With the FDA shortage designations resolved, compounded versions of GLP-1 medications must fit an exception under the federal FD&C Act, such as a documented patient-specific modification, and must meet the Pharmacy Quality Assurance Commission’s sourcing requirements: pharmaceutical-grade base ingredient, valid certificate of analysis, no salt forms, and a pharmacy licensed in Washington. Ask any provider how their pharmacy meets these requirements; a good one will have a clear answer.
Can I get a compounded GLP-1 prescription entirely online in Washington?
Yes. Washington permits prescribing of non-controlled medications after a telehealth evaluation that meets the same standard of care as an in-person visit. No prior in-person appointment is required. You will still need a real medical evaluation; any service offering the medication without one is a red flag.
How can an out-of-state physician treat me in Washington?
Washington participates in the Interstate Medical Licensure Compact, which gives qualified physicians an expedited path to full Washington licensure. A physician licensed this way, as James Simmons, MD is, holds a genuine Washington license and is accountable to the Washington Medical Commission like any other licensee. You can confirm any physician’s license through the Washington State Department of Health’s Provider Credential Search.
Does insurance or Apple Health cover compounded GLP-1s in Washington?
Generally, no. Insurance plans, including Apple Health (Washington’s Medicaid program), do not typically cover compounded medications, which is why this market is almost entirely cash-pay. Gentle Health does not accept insurance; our starting prices ($112, $135, and $169 per month) are dose-tiered cash prices. If you have coverage for a brand GLP-1 through your plan, that is worth exploring with your own physician first.
What should compounded GLP-1 treatment cost in Washington?
Based on published prices as of July 2026, compounded semaglutide from telehealth providers serving Washington generally runs from just over $100 to roughly $250 per month depending on the provider and format, with tirzepatide priced higher, up to roughly $350 for some formats. Watch for membership fees, dose-based price tiers, and introductory rates that increase after the first month; the meaningful number is your all-in monthly cost at your actual dose.
Which pharmacy fills the prescription, and does it matter?
It matters a great deal. Washington requires pharmacies shipping medication into the state to be licensed here, and the commission has said pharmacies dispensing non-compliant compounded semaglutide face disciplinary action. Ask the provider which pharmacy fills their prescriptions and check its license through the Department of Health. Avoid any product sold without a prescription; regulators are explicit that these medications should only be used under the supervision of a licensed healthcare professional.
How do compounded GLP-1s differ from the brand injections?
Compounded semaglutide and tirzepatide are different products from the FDA-approved brand medications: they are prepared by compounding pharmacies for individual patients, are not FDA-approved, and are not reviewed by the FDA for safety, effectiveness, or quality before dispensing. Study results from brand-medication clinical trials should not be assumed to apply to compounded products. Your decision should rest on a conversation with a licensed clinician about your own health.
Current Gentle Health dose tiers and pricing
Gentle Health pricing depends on the dose tier prescribed by your clinician. Current monthly prices are:
Oral compounded semaglutide
| Tier | Daily dose | Monthly price |
|---|---|---|
| Starting | 2-4 mg/day | $112/mo |
| Medium | >4-8 mg/day | $189/mo |
| High dose | >8-12 mg/day | $258/mo |
Injectable compounded semaglutide
| Tier | Weekly dose | Monthly price |
|---|---|---|
| Starting | 0.24-0.48 mg/wk | $135/mo |
| Medium | >0.48-1.2 mg/wk | $159/mo |
| High dose | >1.2-2.4 mg/wk | $199/mo |
Injectable compounded tirzepatide
| Tier | Weekly dose | Monthly price |
|---|---|---|
| Starting | 2.5-5 mg/wk | $169/mo |
| Medium | >5-10 mg/wk | $219/mo |
| High dose | >10-15 mg/wk | $269/mo |
Medication, the initial review by a licensed clinician, video visits and messaging, and overnight refrigerated shipping are included. There is no separate membership fee, and HSA and FSA cards are accepted. Your clinician determines the appropriate medication and dose; the monthly price changes if the prescribed dose moves into a different tier.
Gentle Health serves patients across a growing multistate footprint through clinicians licensed in each patient’s jurisdiction, including Washington.
Reviewed by James Simmons, MD
Compounded medications are not FDA-approved. Treatment subject to medical evaluation.